Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Crexavibart + ogalvibart by Bristol-Myers Squibb for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Crexavibart + ogalvibart is under clinical development by Bristol-Myers Squibb and currently in Phase III for Coronavirus Disease 2019 (COVID-19)....